Systemic Sclerosis

Citations 161-170 of 242 total displayed.

Past content (since Jan 2001):

BASIC SCIENCE
Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine: A. Dooley, B. Gao, N. Bradley, D. J. Abraham, C. M. Black, M. Jacobs, and K. R. Bruckdorfer
Rheumatology 2006; 45: 676-684. [Abstract] [Full Text]

BASIC SCIENCE
Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients: F. K. Tan, X. Zhou, M. D. Mayes, P. Gourh, X. Guo, C. Marcum, L. Jin, and F. C. Arnett, Jr
Rheumatology 2006; 45: 694-702. [Abstract] [Full Text]

CLINICAL
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study: F. Zulian, B. H. Athreya, R. Laxer, A. M. Nelson, S. K. Feitosa de Oliveira, M. G. Punaro, R. Cuttica, G. C. Higgins, L. W. A. Van Suijlekom-Smit, T. L. Moore, C. Lindsley, J. Garcia-Consuegra, M. O. Esteves Hilário, L. Lepore, C. A Silva, C. Machado, S. M. Garay, Y. Uziel, G. Martini, I. Foeldvari, A. Peserico, P. Woo, J. Harper, and for the Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES)
Rheumatology 2006; 45: 614-620. [Abstract] [Full Text]

CASE REPORTS
Management of tenosynovitis in linear scleroderma: D. Hartwright, I. J. Leslie, and S. Clarke
Rheumatology 2006; 45: 640-641. [Extract] [Full Text]

CLINICAL
Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis: Y. Asano, H. Ihn, M. Kubo, M. Jinnin, Y. Mimura, R. Ashida, and K. Tamaki
Rheumatology 2006; 45: 303-307. [Abstract] [Full Text]

CLINICAL
Levels of F₂-isoprostanes in systemic sclerosis: correlation with clinical features: A. Volpe, D. Biasi, P. Caramaschi, W. Mantovani, L. M. Bambara, S. Canestrini, M. Ferrari, G. Poli, M. Degan, A. Carletto, S. Pieropan, and P. Minuz
Rheumatology 2006; 45: 314-320. [Abstract] [Full Text]

BASIC SCIENCE
Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts: H. Ihn, K. Yamane, Y. Asano, M. Jinnin, and K. Tamaki
Rheumatology 2006; 45: 157-165. [Abstract] [Full Text]

CLINICAL
Thymus alterations and systemic sclerosis: C. Ferri, M. Colaci, L. Battolla, D. Giuggioli, and M. Sebastiani
Rheumatology 2006; 45: 72-75. [Abstract] [Full Text]

MATTERS ARISING
Systemic sclerosis, morphoea and breast cancer: G. Mittal, P. Maddison, and W. Williams
Rheumatology 2006; 45: 119-120. [Extract] [Full Text]

BASIC SCIENCE
Circulating levels of active transforming growth factor ß1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score: M. Dziadzio, R. E. Smith, D. J. Abraham, C. M. Black, and C. P. Denton
Rheumatology 2005; 44: 1518-1524. [Abstract] [Full Text]

Collected Resources Home

Rheumatology